ARCHIVES

Trial In Metastatic Disease To Be Unblinded After Regorafenib Meets Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 34 No. 11 | November 25, 2011

Download PDF Visit The Full Archive

Related Articles

NCCS Networker Volume 5 Issue 1, Winter 1991

January 13, 1991

CHOP Evolution Remains Touchy Issues; Contractors Say NCI Plan Too Burdensome

April 22, 1983

“I Can’t Permit Destruction of NSABP,” Fisher Writes

September 9, 1994

FDA Approves Tamoxifen For “Reduction In Incidence,” Avoids Word “Prevention”

November 6, 1998

Five Investigations Probe NIH Radiation Contamination

November 17, 1995

Cancer Control Dilemma: What To do With Successful Demonstrations

September 10, 1976